Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2007

TorreyPines and Eisai Renew Alzheimer's Partnership

  • TorreyPines Therapeutics and Eisai extended their exclusive collaboration that began in February 2005. This agrement focuses on the discovery of novel, small molecules to treat Alzheimer's disease.

    The companies are studying the mechanism of the Alzheimer’s pathogenesis in the hope of finding disease modifying compounds.

    Under the original agreement, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research.  TorreyPines and Eisai may enter into development agreements involving the validated compounds.

    In a separate series of agreements, dating back to 2001, Eisai and TorreyPines are collaborating in a genetics program to discover Alzheimer's disease targets using whole-genome, family-based association screening.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »